×
Gossamer Bio EBIT 2017-2025 | GOSS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Gossamer Bio ebit from 2017 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
Gossamer Bio EBIT 2017-2025 | GOSS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Gossamer Bio ebit from 2017 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$249.5B
Amgen (AMGN)
$159.2B
Gilead Sciences (GILD)
$144.1B
Vertex Pharmaceuticals (VRTX)
$101.9B
Bristol Myers Squibb (BMY)
$98.6B
GSK (GSK)
$81.7B
CSL (CSLLY)
$69.9B
Regeneron Pharmaceuticals (REGN)
$63.4B
Alnylam Pharmaceuticals (ALNY)
$61.3B
Argenex SE (ARGX)
$40.6B
Insmed (INSM)
$28B
BioNTech SE (BNTX)
$26.6B
Royalty Pharma (RPRX)
$21.2B
Biogen (BIIB)
$20.4B
Incyte (INCY)
$16.9B
Genmab (GNMSF)
$16.1B
Genmab (GMAB)
$15.7B
Illumina (ILMN)
$15.3B
Ascendis Pharma (ASND)
$11.8B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.9B
Exelixis (EXEL)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Moderna (MRNA)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.8B
Bio-Techne Corp (TECH)
$8.5B
Halozyme Therapeutics (HALO)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8B